As anti-IL-25R treatment shifts the balance away from suppressive MDSCs and towards anti-tumoral IFNγ+ Th1 and CD8+ T cell infiltration, targeting IL-25-responsive ILC2s might have clinical benefit in CRC patients. The gene discussed is IL25; the disease is colorectal carcinoma.